Form SCHEDULE 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]
SEC Accession No. 0001123292-25-000148
Filing Date
2025-03-20
Accepted
2025-03-20 16:32:25
Documents
1

Document Format Files

Seq Description Document Type Size
1 primary_doc.html SCHEDULE 13G/A  
1 primary_doc.xml SCHEDULE 13G/A 5377
  Complete submission text file 0001123292-25-000148.txt   7418
Mailing Address 333 LAKESIDE DR FOSTER CITY CA 94404
Business Address 333 LAKESIDE DR FOSTER CITY CA 94404 6505743000
GILEAD SCIENCES, INC. (Filed by) CIK: 0000882095 (see all company filings)

EIN.: 943047598 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)

Mailing Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301
Business Address 628 MIDDLEFIELD ROAD PALO ALTO CA 94301 650-249-2727
Kalaris Therapeutics, Inc. (Subject) CIK: 0001754068 (see all company filings)

EIN.: 831971007 | State of Incorp.: DE | Fiscal Year End: 1231
Type: SCHEDULE 13G/A | Act: 34 | File No.: 005-91605 | Film No.: 25756956
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)